314 related articles for article (PubMed ID: 34147248)
1. Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia.
Cardona-Pascual I; Berlana D; Martinez-Valle F; Campany-Herrero D; Montoro-Ronsano JB
Med Clin (Barc); 2022 Apr; 158(7):301-307. PubMed ID: 34147248
[TBL] [Abstract][Full Text] [Related]
2. Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia.
Cardona-Pascual I; Berlana D; Martinez-Valle F; Campany-Herrero D; Montoro-Ronsano JB
Med Clin (Engl Ed); 2022 Apr; 158(7):301-307. PubMed ID: 35531306
[TBL] [Abstract][Full Text] [Related]
3. Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab.
Sánchez-Montalvá A; Sellarés-Nadal J; Espinosa-Pereiro J; Fernández-Hidalgo N; Pérez-Hoyos S; Salvador F; Durà X; Miarons M; Antón A; Eremiev-Eremiev S; Sempere-González A; Monforte-Pallarés A; Bosch-Nicolau P; Augustin S; Sampol J; Guillén-Del-Castillo A; Almirante B
Med Clin (Barc); 2022 Jun; 158(11):509-518. PubMed ID: 34544604
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Tocilizumab in the Treatment of Patients with Moderate to Severe COVID-19 Pneumonia: An Observational Study.
Shastri M; Raval DM; Rathod VM; Patel D
J Assoc Physicians India; 2022 Jan; 70(1):11-12. PubMed ID: 35062798
[TBL] [Abstract][Full Text] [Related]
5. Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison.
Hamed DM; Belhoul KM; Al Maazmi NA; Ghayoor F; Moin M; Al Suwaidi M; Narainen M; Makki M; AbdulRahman M
J Infect Public Health; 2021 Aug; 14(8):985-989. PubMed ID: 34153729
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Early Tocilizumab Effect on Multiorgan Dysfunction in Critically Ill Patients With COVID-19: A Propensity Score-Matched Study.
Aljuhani O; Korayem GB; Altebainawi AF; Al Harthi A; Badreldin HA; Alsalloum MA; Eljaaly K; Alharbi A; Aljehani R; Vishwakarma R; Alenazi AA; Alalawi M; Alissa A; Al Aamer K; Al Enazi H; Almusallam M; Alshehri A; Bukhari R; Alasmari G; AlQahtani MM; Al Shammari S; Alsulaymi HO; Al Sulaiman K
J Intensive Care Med; 2023 Jun; 38(6):534-543. PubMed ID: 36683420
[No Abstract] [Full Text] [Related]
7. Long-term effect of tocilizumab on mortality, readmissions, persistent symptoms and lung function in SARS-CoV-2 patients 1 year after hospital discharge: A matched cohort study.
Cardona-Pascual I; Pallero M; Berlana D; Villar A; Montoro-Ronsano JB; Berastegui C
Respir Med Res; 2023 Nov; 84():101064. PubMed ID: 38029650
[TBL] [Abstract][Full Text] [Related]
8. The association between tocilizumab therapy and the development of thrombosis in critically ill patients with COVID-19: a multicenter, cohort study.
Aljuhani O; Al Sulaiman K; Korayem GB; Altebainawi AF; Alsohimi S; Alqahtani R; Alfaifi S; Alharbi A; AlKhayrat A; Hattan A; Albassam M; Almohammed OA; Alkeraidees A; Alonazi DA; Alsalman WF; Aldamegh G; Alshahrani R; Vishwakarma R
Sci Rep; 2024 Feb; 14(1):3037. PubMed ID: 38321099
[TBL] [Abstract][Full Text] [Related]
9. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M;
JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.
Kyriakopoulos C; Ntritsos G; Gogali A; Milionis H; Evangelou E; Kostikas K
Respirology; 2021 Nov; 26(11):1027-1040. PubMed ID: 34605114
[TBL] [Abstract][Full Text] [Related]
11. Dosing and Administration Strategies of Tocilizumab in Patients With COVID-19: A Retrospective Cohort Analysis.
Steuber TD; Rosandich T; Cadwallader T; Steil L; Belk M; Yendrapalli U; Hassoun A; Edwards J
Ann Pharmacother; 2024 Apr; 58(4):391-397. PubMed ID: 37522616
[TBL] [Abstract][Full Text] [Related]
12. Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study.
Russo G; Solimini A; Zuccalà P; Zingaropoli MA; Carraro A; Pasculli P; Perri V; Marocco R; Kertusha B; Del Borgo C; Del Giudice E; Fondaco L; Tieghi T; D'Agostino C; Oliva A; Vullo V; Ciardi MR; Mastroianni CM; Lichtner M
PLoS One; 2021; 16(9):e0257376. PubMed ID: 34506608
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab in the Management of COVID-19: A Preliminary Report.
Li M; Yoo EJ; Baram M; McArthur M; Skeehan C; Awsare B; George G; Summer R; Zurlo J; Jallo J; Roman J
Am J Med Sci; 2021 Feb; 361(2):208-215. PubMed ID: 33358502
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
15. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital.
Van den Eynde E; Gasch O; Oliva JC; Prieto E; Calzado S; Gomila A; Machado ML; Falgueras L; Ortonobes S; Morón A; Capilla S; Navarro G; Oristrell J; Cervantes M; Navarro M
Infect Dis (Lond); 2021 Apr; 53(4):291-302. PubMed ID: 33620019
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.
Roumier M; Paule R; Vallée A; Rohmer J; Ballester M; Brun AL; Cerf C; Chabi ML; Chinet T; Colombier MA; Farfour E; Fourn E; Géri G; Khau D; Marroun I; Ponsoye M; Roux A; Salvator H; Schoindre Y; Si Larbi AG; Tchérakian C; Vasse M; Verrat A; Zuber B; Couderc LJ; Kahn JE; Groh M; Ackermann F;
J Clin Immunol; 2021 Feb; 41(2):303-314. PubMed ID: 33188624
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab versus anakinra in COVID-19: results from propensity score matching.
Arcani R; Correard F; Suchon P; Kaplanski G; Jean R; Cauchois R; Leprince M; Arcani V; Seguier J; De Sainte Marie B; Andre B; Koubi M; Rossi P; Gayet S; Gobin N; Garrido V; Weiland J; Jouve E; Couderc AL; Villani P; Daumas A
Front Immunol; 2023; 14():1185716. PubMed ID: 37304271
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
Mikulska M; Nicolini LA; Signori A; Di Biagio A; Sepulcri C; Russo C; Dettori S; Berruti M; Sormani MP; Giacobbe DR; Vena A; De Maria A; Dentone C; Taramasso L; Mirabella M; Magnasco L; Mora S; Delfino E; Toscanini F; Balletto E; Alessandrini AI; Baldi F; Briano F; Camera M; Dodi F; Ferrazin A; Labate L; Mazzarello G; Pincino R; Portunato F; Tutino S; Barisione E; Bruzzone B; Orsi A; Schenone E; Rosseti N; Sasso E; Da Rin G; Pelosi P; Beltramini S; Giacomini M; Icardi G; Gratarola A; Bassetti M
PLoS One; 2020; 15(8):e0237831. PubMed ID: 32817707
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab treatment in COVID-19: A prognostic study using propensity score matching.
Güçlü ÖA; Önal U; Akalın H; Öztürk NAA; Belik HÖ; Demirdöğen E; Dilektaşlı AG; Kazak E; Ocakoğlu G; Sağlık İ; Coşkun F; Ediger D; Heper Y; Ursavaş A; Yılmaz E; Uzaslan E; Karadağ M
Adv Clin Exp Med; 2022 Nov; 31(11):1197-1206. PubMed ID: 35951629
[TBL] [Abstract][Full Text] [Related]
20. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
